Thousand Oaks, CA, United States of America

Ian N Foltz

This inventor holds 2 USPTO granted patents and 2 published patent applications and 4 EPO patents. Top assignee: Amgen Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ian N Foltz. Retrieved from https://idiyas.com/inventor/ian-n-foltz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.5

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ian Foltz - Innovator at Amgen Inc.

Introduction

Ian Foltz is an accomplished inventor based in Thousand Oaks, California. He is currently associated with Amgen Inc., a leading biotechnology company. Although he holds no patents at this time, his contributions to the field of biotechnology are noteworthy.

Latest Patents

As of now, Ian Foltz has not registered any patents. This does not diminish his role in the innovative processes at Amgen Inc., where he is involved in various research and development initiatives.

Career Highlights

Ian has made significant strides in his career at Amgen Inc. His work focuses on advancing biotechnological solutions that can improve patient outcomes. His dedication to research and development has positioned him as a valuable asset to his team.

Collaborations

Due to space constraints, the collaborations section will be omitted.

Conclusion

Ian Foltz is a promising inventor whose work at Amgen Inc. reflects his commitment to innovation in biotechnology. His journey in the field is one to watch as he continues to contribute to advancements that may shape the future of healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…